Chatbot to Maximize Hereditary Cancer Genetic Risk Assessment
NCT05562778
This study is recruiting at 4 US sites in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
In this study, the investigators aim to compare a mobile health platform, known as a 'chatbot,' that leverages artificial intelligence and natural language processing to scale communication, to 'usual care' that patients would receive. This comparison will enable the investigators to determine if the chatbot system can improve rates of recommendation for genetic testing among patients at elevated risk of harboring a familial cancer syndrome in an all-Medicaid gynecology clinic.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Gynecologic Cancer
- Hereditary Cancer Syndrome
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Not applicable
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Weill Medical College of Cornell University
- Last updated on ClinicalTrials.gov
- June 23, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
New York · 4
- NYP Brooklyn Methodist Hospital · Brooklyn, NY
- NYP Lower Manhattan Hospital · New York, NY
- Weill Cornell Medicine · New York, NY
- NYP Medical Group Queens · Queens, NY
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.